Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A method for establishing an animal model of bronchopulmonary dysplasia with perfluorooctanoic acid

A technology for perfluorooctanoic acid and dysplasia, which can be used in pharmaceutical formulations, compound screening/testing, preparations for in vivo experiments, etc. It can solve the problems of single pathogenesis and cannot meet the needs of multiple etiological studies, and achieve simplified alveolar structure, interstitial fiber aggravating effect

Active Publication Date: 2022-03-04
PEKING UNIV FIRST HOSPITAL
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Therefore, the technical problem to be solved by the present invention is to overcome the single pathogenic mechanism of bronchopulmonary dysplasia modeling in the prior art, which cannot meet the defects of multiple etiology studies, thereby providing the application and its application of perfluorooctanoic acid in establishing an animal model of bronchopulmonary dysplasia. The construction method, the constructed bronchopulmonary dysplasia model, the pathogenic mechanism not only includes inflammatory response, which may affect fetal development by affecting angiogenesis, cell proliferation and differentiation, etc., allowing to study the pathogenesis of bronchopulmonary dysplasia from multiple aspects and perspectives

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A method for establishing an animal model of bronchopulmonary dysplasia with perfluorooctanoic acid
  • A method for establishing an animal model of bronchopulmonary dysplasia with perfluorooctanoic acid
  • A method for establishing an animal model of bronchopulmonary dysplasia with perfluorooctanoic acid

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Example 1 Construction and verification of an animal model of bronchopulmonary dysplasia

[0042] 1. Materials and methods

[0043] 1.1 Chemicals and Reagents

[0044] Perfluorooctanoic acid, Trizol and reverse transcriptase kits were purchased from Sigma. SYBR Green qPCR kit and BCA protein detection kit were purchased from Takara. HE staining kit was purchased from Beijing Solaibao Technology Co., Ltd. ELISA kits were purchased from Shanghai Xitang Biotechnology Co., Ltd.

[0045] 1.2 Construction of an animal model of bronchopulmonary dysplasia

[0046] Adult SD rats (body weight 250-300 g). Male and female mice were mated 1:2. Adequate water and food supplies were ensured during the study, and the ambient temperature was maintained at 23±2°C.

[0047] PFOA preparation: PFOA high-dose suspension (25mg / kg·d): 300mg PFOA was dissolved in 40ml PBS buffer, adjusted to contain 7.5mg PFOA per 1ml PBS buffer. Perfluorooctanoic acid low-dose suspension (5mg / kg·d): 5m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the field of animal models of bronchopulmonary dysplasia, and provides the application of perfluorooctanoic acid in the establishment of animal models of bronchopulmonary dysplasia. Exposure to perfluorooctanoic acid at 12-18 days of pregnancy can reduce the growth of vascular endothelium in neonatal rats of various days The level of factor A (VEGFA) was significantly down-regulated, combined with the changes in the expression of pulmonary alveolar surfactant protein-B (SP-B) in lung tissue and the results of HE staining of lung tissue pathological sections, it was further confirmed that PFOA exposure has a positive effect on pulmonary vascular development and alveolar development. Has an inhibitory effect. The above results all support that exposure to perfluorooctanoic acid during pregnancy can cause bronchopulmonary dysplasia in offspring mice. In summary, the present invention selects perfluorooctanoic acid (PFOA) widely present in the environment as an inducer. PFOA modeling allows the study of the pathogenesis of bronchopulmonary dysplasia from multiple perspectives.

Description

technical field [0001] The invention relates to the field of animal models of bronchopulmonary dysplasia, in particular to the application of perfluorooctanoic acid in establishing an animal model of bronchopulmonary dysplasia. Background technique [0002] Bronchopulmonary dysplasia (BPD) is one of the most common causes of death in premature infants. Chinese scholars have found through multi-center research statistics that the probability of bronchopulmonary dysplasia in premature infants aged 28-37 weeks in my country is 1.26%. Vascular-related diseases also have a great impact on the later growth of children. Therefore, it is very important to study the pathogenesis of bronchopulmonary dysplasia and find effective treatments for it. At present, there is no uniform modeling method for bronchopulmonary dysplasia, and the experimental animals are not uniform either. [0003] At present, many experimental animal models of bronchopulmonary dysplasia are used: exposure to li...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A01K67/027A61K49/00
CPCA01K67/027A61K49/0008A01K2227/105A01K2267/035A01K2267/0368
Inventor 叶乐平张慧珊卢贺敏
Owner PEKING UNIV FIRST HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com